Domenico Orlando

Domenico Orlando

Auto-generated profile, based on publicly available information

Domenico Orlando

Department of Onco-Haematology and Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2018 in OncoImmunology
Verified
Journal Article
Open access
CQConcetta Quintarelli
Concetta Quintarelli
DODomenico Orlando
Domenico Orlando
IBIolanda Boffa
Iolanda Boffa
MGMarika Guercio
Marika Guercio
VPVinicia Assunta Polito
Vinicia Assunta Polito
ICIgnazio Caruana
Ignazio Caruana
Chimeric antigen receptor (CAR) T-cell therapy has been shown to be dramatically effective in the treatment of B-cell malignancies. However, there are still substantial obstacles to overcome, before similar responses can be achieved in patients with solid tumors. We evaluated both in vitro and in a preclinical murine model the efficacy of different 2nd and 3rd generation CAR constructs targeting GD2, a disial-ganglioside expressed on the surface of neuroblastoma (NB) tumor cells. In order to address potential safety concerns regarding clinical application, an inducible safety switch, namely inducible Caspase-9 (iC9), was also included in the vector constructs. Our data indicate that a 3rd generation CAR incorporating CD28.4-1BB costimulatory domains is associated with improved anti-tumor efficacy as compared with a CAR incorporating the combination of CD28.OX40 domains. We demonstrate that the choice of 4-1BB signaling results into significant amelioration of several CAR T-cell characteristics, including: 1) T-cell exhaustion, 2) basal T-cell activation, 3) in vivo tumor control and 4) T-cell persistence. The fine-tuning of T-cell culture conditions obtained using IL7 and IL15 was found to be synergic with the CAR.GD2 design in increasing the anti-tumor activity of CAR T cells. We also demonstrate that activation of the suicide gene iC9, included in our construct without significantly impairing neither CAR expression nor anti-tumor activity, leads to a prompt induction of apoptosis of GD2.CAR T cells. Altogether, these findings are instrumental in optimizing the function of CAR T-cell products to be employed in the treatment of children with NB.

29 March 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RCRoselia Ciccone
Roselia Ciccone
CQConcetta Quintarelli
Concetta Quintarelli
ACAntonio Camera
Antonio Camera
MPMichele Pezzella
Michele Pezzella
SCSimona Caruso
Simona Caruso
FLFranco Locatelli
Franco Locatelli
Purpose: Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects. We investigated whether chimeric antigen receptor (CAR) T cells directed toward the disialoganglioside GD2 can represent a potentially more effective treatment with reduced long-term side effects. Experimental Design: GD2 expression was evaluated on primary tumor biopsies of MB children by flow cytometry. GD2 expression in MB cells was also evaluated in response to an EZH2 inhibitor (tazemetostat). In in vitro and in vivo models, GD2+ MB cells were targeted by a CAR-GD2.CD28.4-1BBζ (CAR.GD2)-T construct, including the suicide gene inducible caspase-9. Results: GD2 was expressed in 82.68% of MB tumors. The SHH and G3–G4 subtypes expressed the highest levels of GD2, whereas the WNT subtype expressed the lowest. In in vitro coculture assays, CAR.GD2 T cells were able to kill GD2+ MB cells. Pretreatment with tazemetostat upregulated GD2 expression, sensitizing GD2dimMB cells to CAR.GD2 T cells cytotoxic activity. In orthotopic mouse models of MB, intravenously injected CAR.GD2 T cells significantly controlled tumor growth, prolonging the overall survival of treated mice. Moreover, the dimerizing drug AP1903 was able to cross the murine blood–brain barrier and to eliminate both blood-circulating and tumor-infiltrating CAR.GD2 T cells. Conclusions: Our experimental data indicate the potential efficacy of CAR.GD2 T-cell therapy. A phase I/II clinical trial is ongoing in our center (NCT05298995) to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.

22 May 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
FBFatima-Zohra Braikia
Fatima-Zohra Braikia
COChloé Oudinet
Chloé Oudinet
DHDania Haddad
Dania Haddad
ZOZeliha Oruc
Zeliha Oruc
DODomenico Orlando
Domenico Orlando
AKAhmed Amine Khamlichi
Ahmed Amine Khamlichi
Significance: The spatial and temporal control of complex loci’s expression is often effected by distant regulatory elements. At the IgH locus, class switch recombination (CSR) is preceded by transcription of the recombining genes and is controlled by the 3′ regulatory region (3′RR) in a stimulus-dependent manner. Why the 3′RR-mediated up-regulation of transcription is delayed to the mature B-cell stage is unknown. We show that an inducible CTCF insulator is involved in this process. Deletion of the insulator led to specific deregulation of transcription and CSR at earlier developmental stages. Insertion of a promoter downstream of the insulator led to its premature activation. Thus, the 3′RR has developmentally controlled potential to constitutively activate target promoters, but its activity is blocked by the insulator.

5 January 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
VPvirginia di paolo
virginia di paolo
IRIda Russo
Ida Russo
RBRenata Boldrini
Renata Boldrini
LRLucilla Ravà
Lucilla Ravà
MPMarco Pezzullo
Marco Pezzullo
AGAngela Di Giannatale
Angela Di Giannatale
The Intratumoral Microvessel Density (IMVD) is commonly used to quantify tumoral vascularization and is usually assessed by pan-endothelial markers, such as CD31. Endoglin (CD105) is a protein predominantly expressed in proliferating endothelium and the IMVD determined by this marker measures specifically the neovascularization. In this study, we investigated the CD105 expression in pediatric rhabdomyosarcoma and assessed the neovascularization by using the angiogenic ratio IMVD-CD105 to IMVD-CD31. Paraffin-embedded archival tumor specimens were selected from 65 pediatric patients affected by rhabdomyosarcoma. The expression levels of CD105, CD31 and Vascular Endothelial Growth Factor (VEGF) were investigated in 30 cases (18 embryonal and 12 alveolar) available for this study. The IMVD-CD105 to IMVD-CD31 expression ratio was correlated with clinical and pathologic features of these patients. We found a specific expression of endoglin (CD105) in endothelial cells of all the rhabdomyosarcoma specimens analyzed. We observed a significant positive correlation between the IMVD individually measured by CD105 and CD31. The CD105/CD31 expression ratio was significantly higher in patients with lower survival and embryonal histology. Indeed, patients with a CD105/CD31 expression ratio < 1.3 had a significantly increased OS (88%, 95%CI, 60%–97%) compared to patients with higher values (40%, 95%CI, 12%–67%). We did not find any statistical correlation among VEGF and EFS, OS and CD105/CD31 expression ratio. CD105 is expressed on endothelial cells of rhabdomyosarcoma and represent a useful tool to quantify neovascularization in this tumor. If confirmed by further studies, these results will indicate that CD105 is a potential target for combined therapies in rhabdomyosarcoma.

3 June 2024
Verified
Other
Open access
PDF file
RCRoselia Ciccone
Roselia Ciccone
CQConcetta Quintarelli
Concetta Quintarelli
ACAntonio Camera
Antonio Camera
MPMichele Pezzella
Michele Pezzella
SCSimona Caruso
Simona Caruso
FLFranco Locatelli
Franco Locatelli
Supplemental Figure 14. Orthotopic PDX mouse model of human MED-411 FH mCherry/Luc cell line to evaluate anti-tumor activity of CAR.GD2 T-cells.

3 June 2024
Verified
Other
Open access
PDF file
RCRoselia Ciccone
Roselia Ciccone
CQConcetta Quintarelli
Concetta Quintarelli
ACAntonio Camera
Antonio Camera
MPMichele Pezzella
Michele Pezzella
SCSimona Caruso
Simona Caruso
FLFranco Locatelli
Franco Locatelli
Supplemental Figure 9. Real-Time killing assay of CAR.GD2 T-cells vs DAOY-GFP cell line pre-treated with Tazemetostat.